The Innovative Licensing and Access Pathway (ILAP) is focused on getting the most transformative new medicines to patients in the UK health system more quickly.
Patient, public and societal needs are central to its decisions, and they are seeking input on selecting which innovative medicines enter the pathway.
Having read about this outreach, our Director of Research, Policy and Innovation, Dr Karen Noble, said: ”The UK brain tumour community hasn’t seen as many new therapeutics on this pathway as we would like and so we hope that the opportunity to be an ‘insider’ would be one someone in our community would feel able to step up to.”
As a member, you will:
- Read applications, judge how well the product meets the criteria and complete a form to capture your views
- Attend virtual meetings (MS Teams), taking part in the discussions to contribute to decisions about which applications will enter the pathway
- Work alongside experts from the NHS, MHRA and HTAs
The opportunity deadline is 13ᵗʰ September 2025 and you can click here to find out more about the Innovative Licensing and Access Pathway (ILAP). Alternatively, you can email engagement@mhra.gov.uk for further information. Put “ILAP Lay Members” in the subject line.
